Biological Variability in Cartilage Specific Biomarkers in Healthy Volunteers. (COVAR)

January 23, 2015 updated by: Artialis

Evaluation of Biological Variability in Cartilage Specific Biomarkers (Coll2-1, Coll2-1NO2, FIB3-1 and FIB 3-2) in Healthy Volunteers.

The purposes of the study are to assess intra individual biological variability of serum and urinary cartilage specific biomarkers and define the best standardized conditions for blood and urine sampling in the frame of biomarkers dosage.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To assess intra individual biological variability of serum and urinary cartilage specific biomarkers and define the best standardized conditions for blood and urine sampling in the frame of biomarkers dosage. Variation factors assessed are:

  • Fasting condition
  • Sampling time
  • Sampling season
  • Physical activity
  • Duration and temperature of total blood treatment
  • Type of blood collection tube.

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Liege, Belgium, 4000
        • ATC SA, Unité de pharmacologie clinique, CHU Sart Tilman

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Male or female above 18 years

Description

Inclusion Criteria:

  • Male or female, aged above 18 years.
  • Sign an informed consent after being informed
  • Able to follow the instructions of the study

Exclusion Criteria:

  • Serious associated diseases:

    • Severe liver disease
    • Renal failure
    • HIV
    • hepatitis B or C
  • Patient who are the subject of a judicial protection measure or under guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
15 healthy volunteers
Other: serum and urine sample
Other: serum and urine sample
Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Variation of serum and urine sample between baseline, weeks 2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
Time Frame: Baseline and weeks 2, 16, 52 and 68
Change from baseline will be assess by biomarkers dosage using ELISA (Enzyme Linked ImmunoAssay)
Baseline and weeks 2, 16, 52 and 68

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Artialis

Investigators

  • Principal Investigator: Bernard Jandrain, MD, Clinical Pharmacology Unit, ATC sa, Belgium

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2013

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

January 19, 2015

First Submitted That Met QC Criteria

January 23, 2015

First Posted (Estimate)

January 28, 2015

Study Record Updates

Last Update Posted (Estimate)

January 28, 2015

Last Update Submitted That Met QC Criteria

January 23, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • COVAR

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urine Marking

Clinical Trials on serum and urine sample

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe